Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Biogen (BIIB) to $157 from $192 and keeps an Equal Weight rating on the ...

H.C. Wainwright lowered the firm’s price target on Biogen (BIIB) to $241 from $300 and keeps a Buy rating on the shares. The firm says that ...

U.S. President Donald Trump’s threats to slap tariffs on medicines could rattle an industry that has become a cornerstone of ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

Good morning, Boston. Spring training has begun, and here are the five things you need to know, including Biogen cutbacks, CVS's new CEO, Eastern Nazarene sale, spring training, Rat Day, and more Vale ...

In an old rubber fire hose factory in Cambridge, a group of MIT alumni is working on a startup that uses AI to match financial advisors with clients. The company is backed by the same VC that invested ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) traded down 6.8% during trading on Wednesday after Bank Of America (Bofa) lowered ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update.

The Muscular Dystrophy Association celebrates the FDA approval of Evrysdi in tablet form, a more accessible treatment option ...